Log in

BAVARIAN NORDIC/S Stock Forecast, Price & News

0.00 (0.00 %)
(As of 09/24/2020 12:00 AM ET)
Today's Range
Now: $11.00
50-Day Range
MA: $10.86
52-Week Range
Now: $11.00
Average Volume397 shs
Market Capitalization$1.93 billion
P/E Ratio21.57
Dividend YieldN/A
Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases. The company markets non-replicating smallpox vaccine under the IMVAMUNE and IMVANEX names. It is also developing MVA-BN RSV, which is in Phase II clinical trials development stage for the prevention of respiratory syncytial virus; MVA-BN Filo that is in Phase III clinical trials for the treatment of Ebola and Marburg; and MVA-BN HPV that is in Phase I/IIa clinical trials to treat human papillomavirus. In addition, the company develops MVA-BN HIV, a preclinical stage human immunodeficiency virus (HIV) vaccine candidate; MVA-BN HBV, a preclinical stage hepatitis B vaccine candidate; CV301 that is in various clinical trials for the treatment of bladder, colorecta, and pancreatic and colorectal cancers; and MVA-BN Brachyury that is in Phase II clinical trials for the treatment of chordoma and other metastatic cancers. It has license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, the Netherlands, Canada, and internationally. Bavarian Nordic A/S was founded in 1994 and is based in Kvistgård, Denmark.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.67 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic



Sales & Book Value

Annual Sales$99.33 million
Book Value$2.88 per share


Net Income$-51,980,000.00


Market Cap$1.93 billion
Next Earnings Date11/5/2020 (Estimated)
OptionableNot Optionable
0.00 (0.00 %)
(As of 09/24/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BVNRY News and Ratings via Email

Sign-up to receive the latest news and ratings for BVNRY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

BAVARIAN NORDIC/S (OTCMKTS:BVNRY) Frequently Asked Questions

How has BAVARIAN NORDIC/S's stock price been impacted by Coronavirus?

BAVARIAN NORDIC/S's stock was trading at $9.00 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BVNRY shares have increased by 22.2% and is now trading at $11.00.
View which stocks have been most impacted by COVID-19

When is BAVARIAN NORDIC/S's next earnings date?

BAVARIAN NORDIC/S is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for BAVARIAN NORDIC/S

How were BAVARIAN NORDIC/S's earnings last quarter?

BAVARIAN NORDIC/S (OTCMKTS:BVNRY) issued its quarterly earnings data on Wednesday, August, 26th. The company reported $0.11 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.10) by $0.21. The business earned $103.26 million during the quarter, compared to analyst estimates of $32.40 million. BAVARIAN NORDIC/S had a net margin of 31.95% and a return on equity of 13.54%.
View BAVARIAN NORDIC/S's earnings history

Are investors shorting BAVARIAN NORDIC/S?

BAVARIAN NORDIC/S saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 4,900 shares, an increase of 172.2% from the August 15th total of 1,800 shares. Based on an average trading volume of 2,300 shares, the short-interest ratio is presently 2.1 days.
View BAVARIAN NORDIC/S's Short Interest

Who are some of BAVARIAN NORDIC/S's key competitors?

Who are BAVARIAN NORDIC/S's key executives?

BAVARIAN NORDIC/S's management team includes the following people:
  • Dr. Paul Chaplin, CEO & Pres (Age 52)
  • Mr. Henrik Juuel, CFO & Exec. VP (Age 54)
  • Mr. Henrik Birk, COO & Exec. VP (Age 45)
  • Dr. Tommi Kainu, Exec. VP & Chief Bus. Officer (Age 46)
  • Dr. Christopher R. Heery, Chief Medical Officer

What is BAVARIAN NORDIC/S's stock symbol?

BAVARIAN NORDIC/S trades on the OTCMKTS under the ticker symbol "BVNRY."

How do I buy shares of BAVARIAN NORDIC/S?

Shares of BVNRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BAVARIAN NORDIC/S's stock price today?

One share of BVNRY stock can currently be purchased for approximately $11.00.

How big of a company is BAVARIAN NORDIC/S?

BAVARIAN NORDIC/S has a market capitalization of $1.93 billion and generates $99.33 million in revenue each year. The company earns $-51,980,000.00 in net income (profit) each year or ($0.53) on an earnings per share basis. BAVARIAN NORDIC/S employs 419 workers across the globe.

What is BAVARIAN NORDIC/S's official website?

The official website for BAVARIAN NORDIC/S is www.bavarian-nordic.com.

How can I contact BAVARIAN NORDIC/S?

BAVARIAN NORDIC/S's mailing address is Hejreskovvej 10A, Kvistgaard G7, 3490. The company can be reached via phone at 45-3326-8383 or via email at [email protected]

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.